Table 1.
Summary of sample characteristics
| Knight-ADRC | ADNI | UW | UPenn | |
|---|---|---|---|---|
| N | 501 | 394 | 323 | 51 |
| Age (years) Mean ± SD (range) | 69 ± 9 (46–91) | 75 ± 6.9 (55–91) | 67 ± 10 (45–88) | 67 ± 9 (50–86) |
| APOE ε4+ (%) | 37 | 49 | 43 | 61 |
| CDR 0 (%) | 73 | 27 | 61 | 2 |
| Male (%) | 42 | 60 | 48 | 33 |
| ptau | 64 ± 35 (17–229) | 34 ± 18 (7–115) | 37 ± 17 (5–83) | 35 ± 24 (6–116) |
| Tau | 355 ± 229 (85–1624) | 98 ± 57 (28–495) | 77 ± 35 (27–204) | 81 ± 60 (17–351) |
| Aβ42 | 587± 247 (154–1293) | 170 ± 56 (53–300) | 216 ± 73 (64–366) | 177 ± 59 (78–298) |
Age at lumbar puncture (LP), percentage of males, percentage of APOE4 allele carriers, and clinical dementia rating (CDR) at LP date for each sample. For each phenotype the mean in pg/ml with the standard deviation and range is shown. Charles F. and Joanne Knight Alzheimer’s Disease Research Center at University of Washington (Knight-ADRC), Alzheimer’s Disease Neuroimaging Initiative (ADNI) and for the University of Washington, Seattle (UW). Cerebrospinal Fluid (CSF). Case-control (CC).